FMS
Fresenius Sp.ADR (FMS)
NYSE
$23.71+$0.31 (+1.35%)
Price as of Jun 23, 2026 4:10 PM EDT
  • $12.6B
    Market Cap
  • -10.37%
    1-Year Change
  • Medical Care Facilities
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 66
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions

The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.

11/19/2025, 4:57 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$23.39
$23.79
$23.39
1-Year Range
$20.19
$28.77
$23.39
Latest Close$23.39
Change
-$0.20 (-0.86%)
Volume488,456
Market Cap$12.6B
Shares Outstanding537.1M
P/E (TTM)6.96
Diluted EPS (TTM)$3.36
Enterprise Value$11.0B

Information as of 06/22/2026

Company Profile

FRESENIUS MEDICAL CARE AG
FRESENIUS MEDICAL CARE AG
https://www.freseniusmedicalcare.com
$12.6B
Market Cap
$1.2B
Net Income
Sector: Healthcare
Industry: Medical Care Facilities
Else-Kröner-Strasse 1, Bad Homburg, Germany, 61352
49 6172 609 0

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Key Executives

  • Helen Giza
  • Craig Cordola FACHE
  • Joseph E. Turk Jr.
  • Charles Hugh-Jones
  • Martin Fischer

Current Ownership Distribution

  • Institutions643.1M (74.57%)
  • Mutual Funds219.3M (25.43%)
  • Insiders0 (0.00%)
  • Other0 (0.00%)